Novavax

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search

Coordinates: 39°08′14″N 77°13′33″W / 39.1371167°N 77.2258056°W / 39.1371167; -77.2258056

Novavax, Inc.
Public
Traded asNASDAQNVAX
Russell 2000 Component
IndustryBiotechnology
Founded1987; 32 years ago (1987) [1]
Headquarters,
Area served
Worldwide
ProductsVaccines
Number of employees
ca 375[2]
Websitewww.novavax.com

Novavax, Inc. is a clinical-stage vaccine company headquartered in Gaithersburg, Maryland with additional facilities in Rockville, Maryland and Uppsala, Sweden. Novavax is a public company that trades under the symbol "NVAX".[3]

In June 2013, Novavax acquired the Matrix-MTM adjuvant platform with the purchase of Swedish company Isconova AB and renamed it Novavax AB.[4]

In 2015 the company received an $89 million grant from the Bill & Melinda Gates Foundation to support the development of a vaccine against human respiratory syncytial virus for infants via maternal immunization.[5][6][7][8]

In March 2015 the company completed a Phase I trial for its Ebola vaccine candidate.[9]

In September 2016 the company announced that a Phase III trial of its RSV vaccine had failed to meet its endpoints, which caused its share price to fall from $8.34 to $1.40[10] and led the company to lay off 30% of its employees.[2]

As of November 2016 its RSV F vaccine candidate was in three clinical trials.[2][11][12][13]

References[edit]

  1. ^ https://www.bloomberg.com/research/stocks/private/snapshot.asp?privcapId=350381
  2. ^ a b c "Novavax aims to rebound with restructuring, more trials". BioPharma Dive. Retrieved 2017-03-28.
  3. ^ "Novavax, Inc. News Headlines". NASDAQ. Retrieved 8 September 2016.
  4. ^ Taylor, Nick Paul (3 June 2013). "Novavax makes $30M bid for adjuvant business". FiercePharma. Retrieved 9 September 2016.
  5. ^ "http://www.bizjournals.com/washington/blog/2015/09/gaithersburg-biotech-receives-grant-worth-up-to-89.html". www.bizjournals.com. Retrieved 2017-03-28. External link in |title= (help)
  6. ^ "With promising RSV data in hand, Novavax wins $89M Gates grant for PhIII | FierceBiotech". www.fiercebiotech.com. Retrieved 2017-03-28.
  7. ^ "Novavax RSV vaccine found safe for pregnant women, fetus". Reuters. 2016-09-29. Retrieved 2017-03-28.
  8. ^ Herper, Matthew. "Gates Foundation Backs New Shot To Prevent Babies From Dying Of Pneumonia". Forbes. Retrieved 2017-03-28.
  9. ^ "Novavax's Ebola vaccine shows promise in early-stage trial". Reuters. 2017-07-21. Retrieved 2017-03-28.
  10. ^ "Novavax craters after Phase III RSV F vaccine failure; seeks path forward". www.fiercebiotech.com. Retrieved 2017-03-28.
  11. ^ "Novavax hopes to revive RSV vaccine with a new phase 2 trial". www.fiercepharma.com. Retrieved 2017-03-28.
  12. ^ "http://www.bizjournals.com/washington/news/2017/01/19/novavax-starts-new-clinical-trial-in-bid-to-prove.html". www.bizjournals.com. Retrieved 2017-03-28. External link in |title= (help)
  13. ^ "Novavax takes RSV vaccine into Phase III ahead of schedule | FiercePharma". www.fiercepharma.com. Retrieved 2017-03-28.

External links[edit]